FindTrial
Sign In

Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00464282
Enrollment
Unknown
Registered
2007-04-23
Start date
Unknown
Completion date
Unknown
Last updated
2007-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Keywords

Fluorine-18-α-methyltyrosine,, Positron emission tomography,, Fluorodeoxyglucose, Lung cancer,, Amino acid transportor 1,, Ki-67, Proven or suspected non-small cell lung cancer were enrolled in the study

Brief summary

Objective: L-\[3-18F\]-α-methyltyrosine (FMT) is an amino-acid tracer for PET. We evaluated the diagnostic usefulness of 18F-FMT PET in non-small cell lung cancer (NSCLC) patients. Tumor uptake of 18F-FMT PET was compared with 18F-FDG PET and the correlation with L-type amino acid transporter 1 (LAT1) expression also investigated. Method: Fifty patients with NSCLC were enrolled in this study, and a pair of PET study with 18F-FMT and 18F-FDG was performed. LAT1 expression and Ki-67 labeling index of the resected tumors were analyzed by immunohistochemical study.

Interventions

None listed

Sponsors

Gunma University
Lead SponsorOTHER

Study design

Observational model
DEFINED_POPULATION
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
8 Months to 2 Years
Healthy volunteers
No

Inclusion criteria

* proven or suspected non-small cell lung cancer

Exclusion criteria

* uncontrolled diabetes mellitus

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026